Kilitch Drugs (India) Limited

As of June 30, 2026, Kilitch Drugs (India) Limited carries a market capitalization of 6.81B, placing it among publicly traded companies globally. Its enterprise value stands at 6.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kilitch Drugs (India) Limited has 34.96M shares outstanding.

As of June 30, 2026, Kilitch Drugs (India) Limited trades at a trailing price-to-earnings ratio of 22.31.

As of June 30, 2026, Kilitch Drugs (India) Limited trades at an EV/EBITDA multiple of 18.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.01 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.81B versus a market cap of 6.81B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 11.22M in revenue per employee across its workforce of 211.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Kilitch Drugs (India) Limited recorded 98.63M in income tax expense. That works out to an effective tax rate of 25.25, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 390.69M, leaving 300.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Kilitch Drugs (India) Limited's stock has gained approximately 7.71% over the past 52 weeks. The 50-day moving average sits at 199.31, while the 200-day moving average is 175.88.

Over the twelve months ended June 30, 2026, Kilitch Drugs (India) Limited generated 2.37B in revenue and converted that into 300.53M in net income, yielding earnings per share of 8.48. EBITDA reached 362.71M, while operating income came in at 323.98M.

Over the twelve months ended June 30, 2026, Kilitch Drugs (India) Limited posted a gross margin of 47.25, reflecting its pricing power and cost economics. The operating margin of 13.66 and net profit margin of 12.67 provide insight into operational efficiency.

Kilitch Drugs (India) Limited's most recent stock split took place on March 24, 2026 with a 1:2 split ratio.